Dr Davenport

Please please please #slotout

📢 SURMOUNT-5 post-hoc (le Roux CW et al., DOM 2026) tested WHtR <0.53 and BMI <27 kg/m² as treat-to-target thresholds in tirzepatide vs semaglutide. 📊 WHtR <0.53 achieved by 23–34% on tirzepatide vs 14–21% on semaglutide 🟢 77% who reached WHtR <0.53 achieved cardiometabolic low disease activity/remission 📈 OR 2.31 (p<0.001) for disease remission when WHtR target reached 🔴 BMI <27 threshold: NOT associated with meaningful functional outcomes ✅ WHtR is the better target based on this study. Obesity medicine needs treat-to-target thinking. Waist-to-height ratio <0.53 is clinically predictive. BMI alone wasn't enough. 🏁 doi.org/10.1111/dom.70…

Wegovy®▼(semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events in adults with established cardiovascular disease & BMI ≥27 kg/m2. share.google/YrZ9Cm3nVaSB0N…

While waiting for FOCUS, analysis of a matched real world TriNetX cohort of 350,536 patients with #T2D and #CVD followed for up to 5 years revealed reduced rates of legal blindness pubmed.ncbi.nlm.nih.gov/41907810/

The paucity of well powered RCTs with GLP-1 medicines in neuropsychiatric disorders is offset by the recurring tsunami of real world data, here benefits in anxiety, depression and substance use disorders #T2D #obesity thelancet.com/journals/lanps…

1/3: First large study of GLP-1 RAs in liver transplant recipients. Retrospective cohort (TriNetX), propensity-matched, n=541/group. Early post-transplant GLP1RA initiation associated with striking reductions in mortality and hospitalizations -- with no graft safety signal. doi.org/10.1097/TXD.00…

The Joint British Diabetes Societies published a useful clinical guideline for perioperative diabetes management in patients undergoing bariatric surgery. It covers insulin adjustment, glucose monitoring, and medication management around the surgical period. A practical reference for multidisciplinary bariatric teams managing patients with diabetes. doi.org/10.1111/dme.70…

👏Congratulations to @ObesitySociety @ObesityAction @OMAsocial on their Expert Guidance Statement on #obesity pharmacotherapy 👉onlinelibrary.wiley.com/doi/10.1002/ob… It has been a long road since the 2013 guidelines, so this gives us a much needed update to medical #weightmanagement and further cements the consensus among several professional societies to 1. Treat obesity as a disease 2. Prioritize patient-centered care 3. Commit to evidence-based #medicine And thank you to #ObesityJournal for the opportunity to author an accompanying editorial with Dr Donna Ryan 👉onlinelibrary.wiley.com/doi/10.1002/ob…

The BELIEVE study, the efficacy and safety of intravenous bimagrumab and open-label subcutaneous semaglutide, alone or in combination, in adults with #obesity nature.com/articles/s4159…

🧵regarding Lord of the Rings - related traumatic injuries, and whether access to modern Level 1 trauma centers could have decreased morbidity and mortality within the Fellowship. Here we will take a more evidence-based approach to some of the injuries in Middle Earth (1/ )

1. Weight regain is exceptionally common in obesity via lifestyle changes — Dr Kevin Hall while at NIH before it was gutted had modeled how for every kg of weight loss there is an avg 25 kcal decrease in metabolic rate and 100 kcal increase in appetite. This is driven by hormonal and neurological changes in the hypothalamus. 2. Obesity is a chronic complex and relapsing disease. Every intervention whether lifestyle, drug , or surgery meets the brains defense against weight loss. Drugs and surgery operate by reducing the power of that defense described in #1. When you stop the drug that treated the chronic disease, the manifestations of the disease return 3. Obesity as a disease is not intuitive to understand. Without education and training, a physician falls back on beliefs they learned in society such as “obesity is a behaviour”. This is at the root of toxic bias and stigma which has caused harm in countless physician patient interactions. Just as an internist calls upon an EP specialist to offer expert advice, education, and management on atrial fibrillation, a cardiologist could spend some time learning from an obesity specialist and appreciate that perhaps they have insufficient understanding to offer an informed opinion on a topic

🗞️A major new guidance document on steatotic liver disease has just been published online, providing a global, multidisciplinary framework for screening and patient management across the entire disease spectrum. With SLD affecting more than 1 in 3 adults worldwide, the document uses the patient trajectory as its anchor, providing practical recommendations on case finding, risk stratification, referral pathways and stage specific care, from early disease to advanced fibrosis and cirrhosis. All recommendations are categorised as must have or nice to have, enabling adaptation across different healthcare systems and resource settings. 👉Read it now: jhep-reports.eu/action/showPdf… @FrancqueSven

How to navigate the evidence-based road to reducing rates of #obesity associated #cancer nature.com/articles/s4141…

GPs will be “incentivised” to refer eligible patients to weight loss programmes and to prescribe weight loss jabs such as tirzepatide (Mounjaro) as part of the upcoming 2026-27 GP contract bmj.com/content/392/bm…

I didn't know calculations would be part of my job as a doctor but here we go: If you buy 1 Kwikpen of 15 mg Zepbound for $450 and microdose 2.5 mg/wk, this pen will last 24 weeks (or 6 months) and the per-month cost would be $75/mo. Because of Lilly's mandate to refill every 45 days (or else price goes up), ppl should fill it 2 months in a row so that they have a 12-month supply, assuming you remain at 2.5 mg/wk. If you go up to 5 mg/wk, then a single 15-mg Kwikpen will last 3 months ($150/mo) and you should fill 4 months in a row for a 12-month supply, but you can stop filling after the 4th month. 👉In other words, the cost is front-loaded. Think of it as meeting a deductible early in the year. 👉Be sure to refrigerate the pen in between uses and always use a new pen needle for each injection. ⭐️Keep in mind: We do not have any data on stability, sterility, efficacy, or safety of this microdosing method and doing this is directly against manufacturer directions.🚨

I am meeting more and more #obgyn colleagues who are amenable to keeping patients on #GLP1 prepartum all the way up to conception despite current guidelines and package insert They are certainly seeing a side of it that I do not and it is reassuring that real-world experience is not wildly raising a red flag of harm Another recent review concludes: "Accidental periconceptional exposure to GLP-1 RAs may not be associated with an increased risk of adverse pregnancy outcomes, particularly major congenital malformations and pregnancy loss. More high-level evidence will be warranted to confirm these findings and guide clinical decision-making." 👉jogc.com/article/S1701-… #womenshealth #pregnancy #fertility

Cancer and Obesity: Understanding the Connection This EASO COMs webinar explores the complex relationship between obesity and cancer, focusing on evidence across specific cancer types, underlying biological mechanisms, and implications for clinical care. easo.org/video/cancer-a…

Intermittent fasting is no better than regular dieting and only slightly better than doing nothing, according to a Cochrane review of the evidence bmj.com/content/392/bm…

@AdelaCastro222 @RheumNow Exercise is able to reduce/prevent weight regain after glp-1RA cessation? Is there a specific trial demonstrating this? I hadn’t come across one so far. Appreciate if you could let me know. Thank you.

-Weight regain is known when stopping GLP-1 agonists. -Exercise improves wt loss and prevents wt regain. #RWCS2026 @RheumNow

Sugar prices have tumbled to their lowest level in more than five years as weight-loss drugs accelerate a drop in demand by pushing consumers to ditch sweet treats in favour of protein. ft.trib.al/KSGrkUo